CClinicalTrials.gg
CompletedNCT04912544Updated Aug 1, 2022

Facilitating Patient Communication During Noninvasive Ventilation

An interventional study of Noninvasive Ventilation Mask Microphone in Noninvasive Ventilation and Speech Intelligibility, sponsored by University of Utah. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-01.

Sponsored by University of Utah · Not applicable, Interventional, and Device feasibility

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Assessing speech intelligibility in a pilot study of patients speaking with a mask microphone while being treated with standard of care non-invasive ventilation. This is a feasibility study to test the microphone in a real world setting.

Read the detailed description

We will conduct a prospective feasibility study to evaluate speech intelligibility of 10 patients (target distribution of gender: 5 males, 5 females) undergoing standard of care, clinically indicated non-invasive ventilation. Patients will be their own control with and without the ReddyPort™ microphone using a crossover design, with the sequence of conditions randomized (half of patients start with microphone turned on, half start with the microphone turned off). The patients in this study will all receive standard of care. No medical decisions for a change in care will result from the speech recordings obtained during this feasibility study. The speech recordings will be analyzed off-site using a pool of blinded volunteers. The microphone on and off test conditions will not be used to change outcome of the clinical course of care.

02

Conditions studied

  • Noninvasive Ventilation
  • Speech Intelligibility
03

In context

Lead sponsor

University of Utah is the lead sponsor of 969 studies on the registry; 178 are open to participants now.

Of its 107 completed or terminated interventional studies of FDA-regulated products, 62 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age greater than or equal to 18 years
  • Currently hospitalized
  • Awake and able to attempt communication
  • Respiratory failure requiring non-invasive ventilatory support
  • Positive Inspiratory Pressure (PIP) less than or equal to 20 cm H2O
  • Positive End Expiratory Pressure (PEEP) less than or equal to 10 cm H2O
  • FiO2 less than or equal to 0.60
  • Clinical attending physician believes it is safe for the patient to participate
  • Able to consent o If patient cannot consent on the basis of difficulty in being heard and asking questions (as in fact may occur with NIV, a key assumption of this study), then assent will be obtained from the patient with informed consent obtained from a legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  • Tachypnea with RR > 35
  • Increase in PIP, PEEP or FiO2 over the last 2 hours
  • Known to be delirious (clinically obtained CAM score that is positive)
  • Prisoner
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Arm 1

    Patient talking with microphone first turned on and then off

    Device: Noninvasive Ventilation Mask Microphone

  • Experimental
    Arm 2

    Patient talking with microphone first turned off and then on

    Device: Noninvasive Ventilation Mask Microphone

Interventions

  • DeviceNoninvasive Ventilation Mask Microphone

    Noninvasive Ventilation Mask Microphone is turned on to enhance speech intelligibility during the intervention portion of the crossover feasibility study

06

What researchers measure

Primary outcomes

  1. Rating of speech intelligibility

    The 1-5 likert scale developed by Yorkston et al will be used to evaluate speech intelligibility of the device (Yorkston, Kathryn M., David R. Beukelman, and Charles Traynor. Assessment of intelligibility of dysarthric speech. Austin, TX: Pro-ed, 1984.Powell TW. A comparison of English reading passages for elicitation of speech samples from clinical populations. Clin Linguist Phon. 2006;20(2-3):91-7)

    Time frame: Intelligibility will be rated offline by blinded listeners who hear the recording 1-12 weeks after speaking tasks are complete.

Secondary outcomes

  1. Rating of microphone likability

    Subjects will be asked how well they liked using the microphone on a Likert-type scale of 1-5, from extremely unlikable (1) to extremely likable (5)

    Time frame: Immediately after speaking tasks are complete

  2. Rating of speech comprehensibility

    Subjects will be asked how well they could understand the speech on a Likert-type scale of 1-5, from not at all understandable (1) to fully understandable (5)

    Time frame: Immediately after speaking tasks are complete

  3. Rating of how natural the speech sound quality is

    Subjects will be asked how natural the speech sound quality is on a Likert-type scale of 1-5, from not natural (1) to completely natural (5)

    Time frame: Immediately after speaking tasks are complete

07

Study locations

1 site
  • University of Utah
    Salt Lake City, Utah 84112, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04912544
Lead sponsor
University of Utah
Collaborators
National Institute of Nursing Research (NINR), Axon Medical, Inc., Intermountain Medical Center, National Heart, Lung, and Blood Institute (NHLBI)
Responsible party
Sarah Ferguson (Associate Professor, University of Utah) — Principal investigator
First posted
Jun 3, 2021
Start date
Oct 11, 2021
Primary completion
Apr 15, 2022
Completion
May 9, 2022
Last update
Aug 1, 2022

Study contacts

Lara Brewer, PhD
principal investigator · University of Utah

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion